STL 182

Drug Profile

STL 182

Alternative Names: STL-182

Latest Information Update: 24 Oct 2016

Price : $50

At a glance

  • Originator Indiana University School of Medicine; The Laboratory for Drug Discovery in Neurodegeneration
  • Developer Indiana University School of Medicine
  • Class Small molecules
  • Mechanism of Action SMN complex protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Spinal muscular atrophy

Most Recent Events

  • 19 Oct 2016 Preclinical trials in Spinal muscular atrophy in USA (PO) before October 2016
  • 19 Oct 2016 SLT 182 licensed to Spotlight Innovation worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top